Wednesday, 02 Dec 2020

Bangla Version

Pfizer-BioNTech vaccine deliveries could start 'before Christmas'

No icon Pharmaceuticals

Health Desk- 19 Nov 2020: Pfizer Inc PFE.N and BioNTech 22UAy.DE could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.

The vaccine’s efficacy was found to be consistent across different ages and ethnicities - a promising sign given the disease has disproportionately hurt the elderly and certain groups including Black people.

BioNTech Chief Executive Ugur Sahin said the U.S. Food and Drug Administration could grant emergency-use by the middle of December.

Enrico Bucci, a biologist at Temple University in Philadelphia, said ‘A first in the history of mankind: less than a year from the sequence of the virus to the large-scale clinical trial of a vaccine, moreover based on a whole new technique’.